Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
biotech
boston blog main
boston top stories
2
×
boulder/denver blog main
boulder/denver top stories
crispr
detroit blog main
detroit top stories
digital health
gene therapy
glaxosmithkline
indiana blog main
2
×
indiana top stories
life sciences
medicare
national
national blog main
national top stories
new york blog main
new york top stories
nonalcoholic steatohepatitis
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2025
abbvie
ad-comm
adalimumab (humira)
aducanumab
What
bio
new
2
×
remains
2
×
roundup
allogene
approval
biogen’s
biopharmaceutical
cancer
companies
convo
crispr
diversity
drug
earlier
failures
hot
immunotherapy
investors
ipo
juno
littered
million
nash
nearly
news
price
road
shares
snapped
strategy
talk
therapeutics
ticket
utero
years
Language
Current search:
remains
×
new
×
" boston top stories "
×
" indiana blog main "
×
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More